Target antigens for prostate cancer immunotherapy

Cancer and Metastasis Reviews

Volumn 18, Issue 4, 1999, Pages 437-449

  Saffran, Douglas C ^a   Reiter, Robert E ^b   Jakobovits, Aya ^a   Witte, Owen N ^b  

^a UroGenesys Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer vaccines; Monoclonal antibody therapy; Prostate antigens; Prostate cancer

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RITUXIMAB; TRASTUZUMAB; TUMOR ANTIGEN;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; HUMAN; LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; VACCINE PRODUCTION;

ACID PHOSPHATASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0033499199     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006333222424     Document Type: Article

References (103)

1. 1. Lalani elN, Laniado ME, Abel PD: Molecular and cellular biology of prostate cancer. Cancer Metastasis Review 16: 29-66, 1997
2. 2. Slovin SF, Kelly WK, Scher HI: Immunological approaches for the treatment of prostate cancer. Semin Urol Oncol 16: 53-59, 1998
3. 3. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol 16: 2-12, 1998
4. 4. Guinan P, Crispen R, Baumgartner G, Rao R, Totonchi E, Ablin R, John T: Adjuvant immunotherapy with bacillus Calmette-Guerin in prostatic cancer. Urology 14: 561-565, 1979
5. 5. Guinan PD, John T, Baumgartner G, Sundar B, Ablin RJ: Adjuvant immunotherapy (BCG) in stage D prostate cancer. Am J Clin Oncol 5: 65-68, 1982
6. 6. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927-935, 1987
7. 7. Israeli RS, Powell CT, Fair WR, Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227-230, 1993
8. 8. Fair WR, Israeli RS, Heston WD: Prostate-specific membrane antigen. Prostate 32: 140-148, 1997
9. 9. Carter RE, Feldman AR, Coyle JT: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93: 749-753, 1996
10. 10. Su SL, Huang IP, Fair WR, Powell CT, Heston WD: Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 55: 1441-1443, 1995
11. 11. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 58: 4787-4789, 1998
12. 12. Troyer JK, Beckett ML, Wright GL Jr: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30: 232-242, 1997
13. 13. Barren RJ, 3rd, Holmes EH, Boynton AL, Misrock SL, Murphy GP: Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 30: 65-68, 1997
14. 14. Elgamal AA, Troychak MJ, Murphy GP: ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37: 261-269, 1998
15. 15. Texter JH Jr, Neal CE: The role of monoclonal antibody in the management of prostate adenocarcinoma. J Urol 160: 2393-2395, 1998
16. 16. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-3634, 1997
17. 17. Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH: Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 160: 2396-2401, 1998
18. 18. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59: 3192-3198, 1999
19. 19. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58: 4055-4060, 1998
20. 20. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G: Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28: 65-69, 1996
21. 21. Lodge PA, Childs RA, Monahan SJ, McLean JG, Sehgal A, Boynton AL, Salgaller ML, Murphy GP: Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells. J Immunother 22: 346-355, 1999
22. 22. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29: 371-380, 1996
23. 23. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny CM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32: 272-278, 1997
24. 24. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb QE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38: 73-78, 1999
25. 25. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL : Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39: 54-59, 1999
26. 26. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro I, Le Beau MM, Loda M, Witte ON: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95: 1735-1740, 1998
27. 27. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3: 402-408, 1997
28. 28. Mao M, Yu M, Tong JH, Ye J, Zhu J, Huang QH, Fu G, Yu L, Zhao SY, Waxman S, Lanotte M, Wang ZY, Tan JZ, Chan SJ, Chen Z: RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc Natl Acad Sci USA 93: 5910-5914, 1996
29. 29. Gu Z, Shintaku P, Yamashiro J, Said J, Reiter R: Monoclonal antibodies against PSCA detect high levels of PSCA expression in prostate cancer bone metastases. J Urol (suppl) 161: 126, 1999
30. 30. Reiter RE: Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer, 1999 (in press)
31. 31. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM: Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325-3330, 1997
32. 32. Earp HS, Dawson TL, Li X, Yu H: Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115-132, 1995
33. 33. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
34. 34. Disis ML, Cheever MA: HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71: 343-371, 1997
35. 35. Press MF, Cordon-Cardo C, Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990
36. 36. Ware JL, Maygarden SJ, Koontz WW Jr, Strom SC: Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 22: 254-258, 1991
37. 37. Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, Neal DE: p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496-499, 1992
38. 38. Kuhn EJ, Kurnot RA, Sesterhenn TA, Chang EH, Moul JW: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 150: 1427-1433, 1993
39. 39. Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ: HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 28: 827-833, 1997
40. 40. Mark HF, Feldman D, Das S, Kye H, Mark S, Sun CL, Samy M: Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 66: 170-178, 1999
41. 41. Craft N, Shostak Y, Carey M, Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [see comments]. Nat Med 5: 280-285, 1999
42. 42. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C: From HER-2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96: 5458-5463, 1999
43. 43. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995
44. 44. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A, et al.: Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11: 117-127, 1991
45. 45. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts [published erratum appears in Cancer Res 1999 Apr 15; 59(8): 2020]. Cancer Res 58: 2825-2831, 1998
46. 46. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235-2249, 1998
47. 47. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Daniel Coombs D, Baly2 D, Kabbinavar F, Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251, 1999
48. 48. Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 26: 71-77, 1999
49. 49. Pegram MD, Slamon DJ: Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26: 89-95, 1999
50. 50. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER-2/neu-overexpressing metastatic breast cancer. Semin Oncol 26: 78-83, 1999
51. 51. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo C: Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J Urol 152: 2120-2124, 1994
52. 52. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19: 419-427, 1996
53. 53. Li TS, Beling CG: Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 24: 134-144, 1973
54. 54. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R: Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83: 3166-3170, 1986
55. 55. Lundwall A, Lilja H: Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214: 317-322, 1987
56. 56. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991
57. 57. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899-1903, 1985
58. 58. Lee CT, Oesterling JE: Diagnostic markers of prostate can-cer: utility of prostate-specific antigen in diagnosis and staging. Semin Surg Oncol 11: 23-35, 1995
59. 59. Polascik TJ, Oestereling JE, Partin AW: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162: 293-306, 1999
60. 60. Pang S, Dannull J, Kaboo R, Xie Y, Tso C-L, Michel K, deKernion JB, Belldegrun AS: Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 57: 495-499, 1997
61. 61. Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB, Shoemaker H: Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine [published erratum appears in Oncogene 1999 Apr 8; 18(14): 2411]. Oncogene 17: 3125-3135, 1998
62. 62. Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG: Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T-lymphocytes. Cancer Immunol Immunother 42: 362-368, 1996
63. 63. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG: Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci USA 94: 6369-6374, 1997
64. 64. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA: Identification of Her-2/Neu CTL epitopes using double trangenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol 52: 109-118, 1997
65. 65. Xue BH, Zhang Y, Sosman JA, Peace DJ: Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen [see comments]. Prostate 30: 73-78, 1997
66. 66. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY: In vitro generation of human cytotoxic T-lymphocytes specific for peptides derived from prostate-specific antigen [see comments]. J Natl Cancer Inst 89: 293-300, 1997
67. 67. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY: Generation of human cytolytic T-lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 161: 3186-3194, 1998
68. 68. Rammensee HG, Falk K, Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11: 213-244, 1993
69. 69. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53: 260-266, 1999
70. 70. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA: A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 63: 231-237, 1995
71. 71. Harris DT, Matyas GR, Gomella LG, Talor E, Winship MD, Spitler LE, Mastrangelo MJ: Immunologic approaches to the treatment of prostate cancer [In Process Citation]. Semin Oncol 26: 439-447, 1999
72. 72. Sinha AA, Sackrison JL, DeLeon OF, Wilson MJ, Gleason DF: Antibody immunoglobulin G (IgG) against human prostatic-specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis. Anat Rec 245: 652-661, 1996
73. 73. Sinha AA, Quast BJ, Reddy PK, Elson MK, Wilson MJ: Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2′-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anticancer Res 19: 893-902, 1999
74. 74. Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, Hood L, Wang K: Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Nat Acad Arts Sciences 96: 3114-3119, 1999
75. 75. Yousef GM, Obiezu CV, Luo LY, Black MH, Diamandis EP: Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 59: 4252-4256, 1999
76. 76. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS: Prostate-localized and androgen-regulated expression of the membranebound serine protease TMPRSS2. Cancer Res 59: 4180-4184, 1999
77. 77. Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C, Antonarakis SE: Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 44: 309-320, 1997
78. 78. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, Parham GP, O'Brien TJ: Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 57: 2884-2887, 1997
79. 79. Gutman E, Sproul E, Gutman A: Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Amer J Cancer 28: 485, 1936
80. 80. Vihko P, Virkkunen P, Henttu P, Roiko K, Solin T, Huhtala ML: Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 236: 275-281, 1988
81. 81. Lam KW, Li CY, Yam LT, Sun T, Lee G, Ziesmer S: Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 15: 13-21, 1989
82. 82. Solin T, Kontturi M, Pohlmann R, Vihko P: Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochim Biophys Acta (1048): 72-77, 1990
83. 83. Sinha AA, Quast BJ, Wilson MJ, Reddy PK, Fernandes FT, Ewing SL, Gleason DF: Immunocytochemical localization of an immunoconjugate (antibody IgG against prostatic acid phosphatase conjugated to 5-fluoro-2′-deoxyuridine) in human prostate tumors. Anticancer Res 18: 1385-1392, 1998
84. 84. Jacobs EL, Haskell CM: Clinical use of tumor markers in oncology. Curr Probl Cancer 15: 299-360, 1991
85. 85. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization. Proc Natl Acad Sci USA 159: 3113-3117, 1997
86. 86. Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA: Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis implications for prostate cancer therapy. J Immunol 159: 472-480, 1997
87. 87. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC: Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36: 129-138, 1998
88. 88. Deguchi T, Chu TM, Leong SS, Horoszewicz JS, Lee CL: Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. Cancer Res 46: 3751-3755, 1986
89. 89. Deguchi T, Chu TM, Leong SS, Horozsewicz JS, Lee CL: Potential therapeutic effect of adriamycin-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. J Urol 137: 353-358, 1987
90. 90. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, et al.: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int J Cancer 63: 883-885, 1995
91. 91. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T-lymphocytes on a human melanoma. J Exp Med 182: 689-698, 1995
92. 92. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T-lymphocytes. Immunity 2: 167-175, 1995
93. 93. Chen ME, Lin SH, Chung LW, Sikes RA: Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 273: 17618-17625, 1998
94. 94. Vasmatzis G, Essand M, Brinkmann U, Lee B, Pastan I: Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis. Proc Natl Acad Sci USA 95: 300-304, 1998
95. 95. Brinkmann U, Vasmatzis G, Lee B, Yerushalmi N, Essand M, Pastan I: PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc Natl Acad Sci USA 95: 10757-10762, 1998
96. 96. Brinkmann U, Vasmatzis G, Lee B, Pastan I: Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 59: 1445-1448, 1999
97. 97. Holliger P, Hoogenboom H: Antibodies come back from the brink [news]. Nat Biotechnol 16: 1015-1016, 1998
98. 98. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MU, Davis CG, Zsebo KM, Jakobovits A: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice [published erratum appears in Nat Genet 1997 Aug; 16(4): 410]. Nat Genet 15: 146-156, 1997
99. 99. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236-1243, 1999
100. 100. Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, Bod E, van der Vuurst de Vries AR, Loyson SA, Helfrich W, van Berge Henegouwen GP, van Meijer M, de Kruif J, Logtenberg T: A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 17: 276-281, 1999
101. 101. Persidis A: Functional antigenics. Nat Biotechnol 16: 305-307, 1998
102. 102. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162: 2227-2234, 1999
103. 103. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL: Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46: 681-686; discussion 686-687, 1995